Human cd6 binding molecules
AssigneeThe Cleveland Clinic Foundation
InventorFeng LIN
Life of this patent
Estimating the term…
Abstract
Provided herein are human Cluster of Differentiation 6 (CD6) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human CD6 binding molecules (e.g., nanobodies) having a first, and optionally a second, single monomeric variable antibody domain (SMVAD) that comprises certain CDRs, and methods for using such molecules to treat T-cell related diseases (e.g., cancer, such as T-cell lymphoma). In certain embodiments, the SMVAD comprises camelid, human, or humanized framework regions.
Claims33
A composition comprising a human Cluster of Differentiation 6 (CD6) binding molecule, or one or more nucleic acid molecules encoding said human CD6 binding molecule,
- wherein said human CD6 binding molecule comprises a first single monomeric variable antibody domain (SMVAD) that comprises:
- A) a CDR1 amino acid sequence comprising SEQ ID NO:2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, or 78;
- or SEQ ID NO:2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, or 78;
- with one with one or two conservative amino acid changes,
- B) a CDR2 amino acid sequence comprising SEQ ID NO:3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, or 79;
- or SEQ ID NO:3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, or 79 with one or two conservative amino acid changes, and
- C) a CDR3 amino acid sequence comprising SEQ ID NO:4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, or 80;
- or SEQ ID NO:4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, or 80 with one with one or two conservative amino acid changes.
Dependencies are inferred from the claim text.